Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

PLSE

Pulse Biosciences Inc

Apr 26 • 04:00PM ET

7.19

Dollar change +0.50
Percentage change 7.47	%

Healthcare • Medical Instruments & Supplies • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN VTWO ISMD IWO IWC RYLD VTWV

Index	RUT	P/E	-	EPS (ttm)	-0.89	Insider Own	70.66%	Shs Outstand	55.14M	Perf Week	0.00%
Market Cap	397.10M	Forward P/E	-	EPS next Y	-	Insider Trans	2.79%	Shs Float	16.20M	Perf Month	-14.40%
Income	-42.21M	PEG	-	EPS next Q	-	Inst Own	8.07%	Short Float	17.94%	Perf Quarter	-15.61%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-15.31%	Short Ratio	17.77	Perf Half Y	80.20%
Book/sh	0.80	P/B	8.94	EPS next Y	-	ROA	-59.70%	Short Interest	2.91M	Perf Year	23.33%
Cash/sh	0.80	P/C	8.95	EPS next 5Y	-	ROE	-200.47%	52W Range	3.78 - 13.62	Perf YTD	-41.26%
Dividend Est.	-	P/FCF	-	EPS past 5Y	16.76%	ROI	-80.48%	52W High	-47.21%	Beta	1.75
Dividend TTM	-	Quick Ratio	6.76	Sales past 5Y	-30.13%	Gross Margin	-4734.38%	52W Low	90.21%	ATR (14)	0.55
Dividend Ex-Date	-	Current Ratio	6.76	EPS Y/Y TTM	49.14%	Oper. Margin	0.00%	RSI (14)	41.00	Volatility	5.44% 7.35%
Employees	56	Debt/Eq	0.21	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	3.00	Target Price	5.00
Option/Short	Yes / Yes	LT Debt/Eq	0.18	EPS Q/Q	12.27%	Payout	-	Rel Volume	0.44	Prev Close	6.69
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	100.00%	Earnings	May 07 AMC	Avg Volume	163.52K	Price	7.19
SMA20	-3.70%	SMA50	-17.71%	SMA200	-3.35%	Trades		Volume	71,215	Change	7.47%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-27-21	Initiated	Stephens	Overweight	$28
Mar-11-21	Initiated	Maxim Group	Buy	$40
Jan-26-21	Reiterated	H.C. Wainwright	Buy	$16 → $40
May-12-20	Upgrade	H.C. Wainwright	Neutral → Buy	$6 → $16
Feb-14-20	Downgrade	H.C. Wainwright	Buy → Neutral	$26 → $6
Feb-25-19	Initiated	H.C. Wainwright	Buy	$27

Apr-24-24 04:05PM	Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024 (Business Wire)
Apr-01-24 04:19PM	Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2023 Earnings Call Transcript (Insider Monkey) -8.27%
Mar-29-24 06:30AM	Q4 2023 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-28-24 10:53PM	PLSE Stock Earnings: Pulse Biosciences Reported Results for Q4 2023 (InvestorPlace)
05:51PM	Pulse Biosciences Inc (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023 (GuruFocus.com)
04:12PM	Loading…
04:12PM	Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results (Business Wire)
04:10PM	Pulse Biosciences Announces Plans to Initiate a Rights Offering (Business Wire)
Mar-14-24 04:05PM	Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024 (Business Wire)
Mar-08-24 01:17PM	Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX nsPFA Percutaneous Electrode System (Business Wire)
Feb-14-24 08:00AM	Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX nsPFA 360 Cardiac Catheter First-in-Human Feasibility Study (Business Wire) +12.56%
Jan-31-24 08:00AM	Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium (Business Wire)
Jan-02-24 08:00AM	Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp (Business Wire) -9.97%
Dec-20-23 08:00AM	Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation (nsPFA) Cardiac Catheter (Business Wire) -7.11%
Nov-21-23 08:00AM	Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode (Business Wire) +5.59%
Nov-15-23 04:05PM	Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference (Business Wire) +9.62%
12:52PM	Loading…
Nov-14-23 12:52PM	Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2023 Earnings Call Transcript (Insider Monkey) +7.58%
02:15AM	Q3 2023 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-13-23 11:13AM	Pulse Biosciences Inc (PLSE) Reports Decrease in Q3 Losses and Advances in Cardiac Device ... (GuruFocus.com)
08:00AM	Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results (Business Wire)
Nov-10-23 04:56PM	UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call (Business Wire) +11.57%
Oct-30-23 04:05PM	Pulse Biosciences Schedules Third Quarter 2023 Financial Results Conference Call for November 13, 2023 (Business Wire) +5.76%
Oct-24-23 08:00AM	Pulse Biosciences Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery (Business Wire)
Oct-02-23 08:00AM	Pulse Biosciences Announces Collaboration with CardioNXT for nsPFA First-in-Human Atrial Fibrillation Study (Business Wire)
Sep-29-23 08:00AM	Pulse Biosciences Nanosecond Pulsed Field Ablation (nsPFA) Circumferential Catheter System to be Featured in a Presentation at the Global EP Summit (Business Wire) -7.57%
Sep-27-23 08:00AM	Pulse Biosciences First Study in a Surgical Application of Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Two Poster Presentations at the American Thyroid Association Annual Meeting (Business Wire)
Sep-07-23 04:05PM	Pulse Biosciences to Present at Gilmartin Group Emerging Growth Showcase (Business Wire)
Aug-24-23 04:05PM	Pulse Biosciences Clarifies Details of Recent S-3 Filing (Business Wire) -8.95%
Aug-17-23 09:31AM	15 Best-Performing Stocks in the Last 12 Months (Insider Monkey)
Aug-11-23 06:28AM	Q2 2023 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) +5.56%
Aug-10-23 04:05PM	Pulse Biosciences Reports Business Updates and Second Quarter 2023 Financial Results (Business Wire) -5.66%
09:35AM	Loading…
Jul-30-23 09:35AM	Pulse Biosciences, Inc. (NASDAQ:PLSE) insiders have had a fantastic week as stock increased 31%, and they haven't stopped buying (Simply Wall St.)
Jul-27-23 04:05PM	Pulse Biosciences Schedules Second Quarter 2023 Financial Results Conference Call for August 10, 2023 (Business Wire)
May-22-23 09:30AM	11 Stocks with Heavy Insider Buying in 2023 (Insider Monkey) -7.94%
May-18-23 07:00AM	Pulse Biosciences Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Several Presentations at The Heart Rhythm 2023 Annual Meeting (Business Wire) -5.73%
May-16-23 12:01PM	Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-12-23 07:43AM	Q1 2023 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) +6.31%
May-11-23 04:05PM	Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results (Business Wire) -8.31%
May-10-23 09:29AM	Pulse Biosciences, Inc. Announces Planned Redemption of Warrants (Business Wire)
May-03-23 08:00AM	Pulse Biosciences, Inc. Appoints Dr. Gan Dunnington as Chief Medical Officer (Business Wire) +19.19%
May-01-23 08:00AM	Pulse Biosciences Announces $65 Million Private Placement (Business Wire) +5.75%
Apr-27-23 04:05PM	Pulse Biosciences Schedules First Quarter 2023 Financial Results Conference Call for May 11, 2023 (Business Wire)
Apr-20-23 06:04AM	As Pulse Biosciences, Inc. (NASDAQ:PLSE) hits US$217m market cap, insiders may be dismayed about not purchasing higher quantities (Simply Wall St.)
Apr-05-23 07:46PM	Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-30-23 04:05PM	Pulse Biosciences Reports Fourth Quarter & Full Year 2022 Financial Results (Business Wire)
Mar-10-23 08:30AM	Even after rising 18% this past week, Pulse Biosciences (NASDAQ:PLSE) shareholders are still down 79% over the past five years (Simply Wall St.) +8.78%
Mar-02-23 04:05PM	Pulse Biosciences Schedules Fourth Quarter & Full Year 2022 Financial Results Conference Call for March 30, 2023 (Business Wire)
Feb-02-23 08:00AM	Pulse Biosciences Announces Its Novel Nanosecond Pulsed Field Ablation System Will Be Highlighted at the 2023 AF Symposium (Business Wire)
Dec-10-22 07:24AM	Pulse Biosciences, Inc. (NASDAQ:PLSE) insiders have recently purchased stock and their bets paid off last week as company hit US$108m market cap (Simply Wall St.)
Nov-10-22 04:05PM	Pulse Biosciences Reports Third Quarter 2022 Financial Results (Business Wire) +13.04%
Oct-27-22 04:05PM	Pulse Biosciences Schedules Third Quarter 2022 Financial Results Conference Call for November 10, 2022 (Business Wire) -5.02%
Oct-14-22 06:17AM	Insider Buying: The Pulse Biosciences, Inc. (NASDAQ:PLSE) Chief Strategy Officer & Director Just Bought 70% More Shares (Simply Wall St.) -5.83%
Oct-06-22 08:00AM	Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions (Business Wire) -9.81%
Oct-01-22 08:50AM	Pulse Biosciences (NASDAQ:PLSE) adds US$29m to market cap in the past 7 days, though investors from a year ago are still down 89% (Simply Wall St.)
Sep-26-22 10:00AM	Pulse Biosciences Lead Therapeutic System Scores FDA Approval For Sebaceous Hyperplasia (Benzinga) +18.30%
08:00AM	Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia (Business Wire)
Sep-21-22 10:03AM	Pulse Biosciences Shifts Core Technology Focus, Reduces Dermatologic Footprint (Benzinga) +7.19%
Sep-20-22 04:26PM	Pulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation (Business Wire)
Aug-10-22 05:25PM	Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +6.88%
04:05PM	Pulse Biosciences Reports Second Quarter 2022 Financial Results (Business Wire)
Aug-04-22 08:00AM	Pulse Biosciences Receives FDA 510(k) Clearance of Expanded Energy Settings for use with the CellFX® System (Business Wire)
Jul-27-22 04:05PM	Pulse Biosciences Schedules Second Quarter 2022 Financial Results Conference Call for August 10, 2022 (Business Wire)
Jun-16-22 04:15PM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.37%
Jun-09-22 04:43PM	Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering (Business Wire)
Jun-03-22 08:00AM	Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering (Business Wire)
May-19-22 08:00AM	Pulse Biosciences, Inc. Announces Changes to its Rights Offering (Business Wire)
May-13-22 01:44PM	Stock rebound uncertain for U.S. biotechs as risks multiply for investors (American City Business Journals) +14.86%
May-11-22 06:05PM	Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -17.17%
04:05PM	Pulse Biosciences Reports First Quarter 2022 Financial Results (Business Wire)
May-04-22 08:00AM	Pulse Biosciences, Inc. Announces Commencement of Rights Offering (Business Wire)
Apr-28-22 08:00AM	Pulse Biosciences Schedules First Quarter 2022 Financial Results Conference Call for May 11, 2022 (Business Wire)
Apr-26-22 08:00AM	Pulse Biosciences to Present New Data on Nano-Pulse Stimulation Procedure for Sebaceous Hyperplasia and for Focal Epithelial Hyperplasia at 2022 American Society of Laser Medicine and Surgery Annual Conference (Business Wire) -8.20%
Apr-14-22 04:05PM	Pulse Biosciences, Inc. Announces Rights Offering (Business Wire) -6.72%
Mar-31-22 05:25PM	Pulse Biosciences, Inc (PLSE) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Pulse Biosciences Reports Fourth Quarter & Full Year 2021 Financial Results (Business Wire)
Mar-21-22 04:05PM	Pulse Biosciences Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call for March 31, 2022 (Business Wire) -9.89%
Mar-17-22 06:57AM	A Pulse Biosciences, Inc. (NASDAQ:PLSE) insider increased their holdings by 25% last year (Simply Wall St.) +8.56%
Feb-15-22 08:00AM	Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer (Business Wire)
Feb-08-22 12:37PM	What Is Happening With Pulse Biosciences Stock Today? (Benzinga) -34.44%
08:45AM	Pulse Biosciences Provides an Update on Recent FDA 510(k) Submission (Business Wire)
Feb-01-22 04:05PM	Pulse Biosciences to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (Business Wire)
Jan-11-22 07:00AM	Pulse Biosciences Announces Preliminary Fourth Quarter and Full Year 2021 Financial and Operational Results (Business Wire)
Dec-28-21 02:38AM	Destra Investment Trust Buys ThredUp Inc, Etsy Inc, Riskified, Sells , , 2U Inc (GuruFocus.com)
Dec-17-21 09:20AM	What Type Of Shareholders Own The Most Number of Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares? (Simply Wall St.)
Nov-25-21 10:00AM	Pulse Biosciences, Inc (PLSE)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
Nov-18-21 04:05PM	Pulse Biosciences to Participate in the Stephens Annual Investment Conference (Business Wire) -5.01%
Nov-15-21 04:05PM	Pulse Biosciences Reports Third Quarter 2021 Financial Results (Business Wire)
Nov-04-21 04:05PM	Pulse Biosciences to Present at the Stifel 2021 Virtual Healthcare Conference (Business Wire)
Nov-02-21 04:05PM	Pulse Biosciences Schedules Third Quarter 2021 Financial Results Conference Call for November 15, 2021 (Business Wire)
Oct-05-21 08:00AM	Pulse Biosciences Appoints Laureen DeBuono to Its Board of Directors (Business Wire)
Sep-02-21 04:05PM	Pulse Biosciences to Participate in the H.C. Wainwright Global Investment Conference (Business Wire)
12:43PM	Is Pulse Biosciences (NASDAQ:PLSE) Weighed On By Its Debt Load? (Simply Wall St.)
Aug-19-21 04:05PM	Pulse Biosciences Announces Appointment of Mitchell E. Levinson as Chief Strategy Officer (Business Wire)
Aug-09-21 04:05PM	Pulse Biosciences Reports Second Quarter 2021 Financial Results (Business Wire)
Jul-26-21 04:05PM	Pulse Biosciences Schedules Second Quarter 2021 Financial Results Conference Call for August 9, 2021 (Business Wire)
Jul-06-21 01:34AM	Robert Duggan Is The Independent Chairman of the Board of Pulse Biosciences, Inc. (NASDAQ:PLSE) And They Just Picked Up 25% More Shares (Simply Wall St.)
Jul-01-21 05:45PM	Why Pulse Biosciences Stock Moved Higher Thursday (Motley Fool) +26.95%
08:00AM	Pulse Biosciences Announces $50 Million Private Placement (Business Wire)
Jun-30-21 10:56AM	Want to Buy Pulse Biosciences (NASDAQ: PLSE) Stock? See This First. (Benzinga)
10:20AM	Pulse Biosciences Announces First CellFX® Procedure Performed in Canada (Business Wire)
Jun-11-21 06:17AM	Moving Average Crossover Alert: Pulse Biosciences (PLSE) (Zacks)

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DUGGAN ROBERT W	Director	Dec 12 '23	Buy	9.15	17,999	164,691	36,984,179	Dec 14 07:37 PM
DUGGAN ROBERT W	Director	Dec 11 '23	Buy	9.36	90,118	843,504	36,966,180	Dec 13 06:03 PM
DUGGAN ROBERT W	Director	Dec 08 '23	Buy	9.54	116,656	1,112,898	36,876,062	Dec 12 07:28 PM
DUGGAN ROBERT W	Director	Dec 07 '23	Buy	9.19	74,852	687,890	36,759,406	Dec 11 08:13 PM
DUGGAN ROBERT W	Director	Dec 06 '23	Option Exercise	5.95	9,933	59,101	36,601,741	Dec 08 07:38 PM
DUGGAN ROBERT W	Director	Dec 06 '23	Buy	9.06	82,813	750,286	36,684,554	Dec 08 07:38 PM
DUGGAN ROBERT W	Director	Dec 05 '23	Buy	9.34	66,021	616,636	351,565	Dec 07 08:34 PM
DUGGAN ROBERT W	Director	Dec 04 '23	Option Exercise	10.66	40,347	430,099	36,591,808	Dec 06 07:54 PM
DUGGAN ROBERT W	Director	Dec 04 '23	Buy	10.38	27,000	280,260	285,544	Dec 06 07:54 PM
DUGGAN ROBERT W	Director	Dec 01 '23	Buy	9.07	45,600	413,592	258,544	Dec 05 08:31 PM
DUGGAN ROBERT W	Director	Nov 30 '23	Buy	9.06	152,944	1,385,673	212,944	Dec 04 07:37 PM
DUGGAN ROBERT W	Director	Nov 29 '23	Option Exercise	5.95	1,667	9,919	36,392,861	Dec 01 07:36 PM
DUGGAN ROBERT W	Director	Nov 29 '23	Buy	9.44	158,600	1,497,184	36,551,461	Dec 01 07:36 PM
DUGGAN ROBERT W	Director	Nov 29 '23	Buy	9.21	60,000	552,600	60,000	Dec 01 07:36 PM
DUGGAN ROBERT W	Director	Nov 28 '23	Buy	8.98	124,397	1,117,085	36,391,194	Nov 30 07:25 PM
DUGGAN ROBERT W	Director	Nov 17 '23	Buy	6.10	20,241	123,470	36,266,797	Nov 20 08:56 PM
Danahy Kevin Patrick	Chief Executive Officer	Nov 16 '23	Buy	6.52	5,393	35,156	35,887	Nov 17 09:11 AM
Levinson Mitchell E.	Chief Strategy Officer	Nov 15 '23	Buy	5.91	13,539	80,058	9,135	Nov 17 09:10 AM
Levinson Mitchell E.	Chief Strategy Officer	Nov 15 '23	Buy	5.87	4,261	25,033	73,027	Nov 17 09:10 AM
Zanganeh Mahkam	Director	Nov 13 '23	Option Exercise	2.14	76,075	162,800	604,911	Nov 15 05:37 PM
DUGGAN ROBERT W	Director	Nov 07 '23	Option Exercise	5.95	13,265	78,927	36,246,556	Nov 09 06:32 PM
DUGGAN ROBERT W	Director	Aug 25 '23	Option Exercise	5.95	1,667	9,919	36,233,291	Aug 28 08:08 PM
DUGGAN ROBERT W	Director	Jul 25 '23	Option Exercise	5.95	1,667	9,919	36,231,624	Jul 27 09:09 AM
DUGGAN ROBERT W	Director	Jul 07 '23	Option Exercise	2.23	67,133	150,012	36,229,957	Jul 07 06:26 PM
DUGGAN ROBERT W	Director	Jul 05 '23	Option Exercise	2.14	65,000	139,100	36,162,824	Jul 07 06:26 PM
DUGGAN ROBERT W	Director	May 09 '23	Buy	6.51	10,022,937	65,249,320	30,414,661	May 10 05:41 PM

Open in Screener

SMMT

Summit Therapeutics Inc

Apr 26 • 04:00PM ET

3.86

Dollar change +0.31
Percentage change 8.73	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

SMMT Summit Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IWO IBB SCHA VHT LABU SBIO VTWO

Index	RUT	P/E	-	EPS (ttm)	-1.54	Insider Own	88.17%	Shs Outstand	701.66M	Perf Week	10.29%
Market Cap	2.71B	Forward P/E	-	EPS next Y	-0.29	Insider Trans	0.04%	Shs Float	82.98M	Perf Month	2.93%
Income	-614.96M	PEG	-	EPS next Q	-0.06	Inst Own	4.63%	Short Float	27.59%	Perf Quarter	-0.52%
Sales	0.00M	P/S	-	EPS this Y	75.76%	Inst Trans	-29.21%	Short Ratio	10.50	Perf Half Y	105.32%
Book/sh	0.11	P/B	34.86	EPS next Y	-20.83%	ROA	-141.84%	Short Interest	22.90M	Perf Year	184.87%
Cash/sh	0.27	P/C	14.54	EPS next 5Y	-	ROE	-601.88%	52W Range	1.30 - 5.22	Perf YTD	47.89%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-339.79%	52W High	-26.05%	Beta	-1.11
Dividend TTM	-	Quick Ratio	9.30	Sales past 5Y	-28.65%	Gross Margin	-	52W Low	196.92%	ATR (14)	0.30
Dividend Ex-Date	-	Current Ratio	9.30	EPS Y/Y TTM	-147.47%	Oper. Margin	0.00%	RSI (14)	51.84	Volatility	8.05% 7.69%
Employees	105	Debt/Eq	1.37	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	8.00
Option/Short	Yes / Yes	LT Debt/Eq	1.33	EPS Q/Q	42.70%	Payout	-	Rel Volume	0.64	Prev Close	3.55
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Feb 20 BMO	Avg Volume	2.18M	Price	3.86
SMA20	2.66%	SMA50	-5.40%	SMA200	40.40%	Trades		Volume	1,388,283	Change	8.73%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-26-24	Initiated	Stifel	Buy	$8
Jun-28-18	Downgrade	Janney	Buy → Neutral
May-02-18	Initiated	Janney	Buy
Apr-12-18	Reiterated	Needham	Buy	$30 → $27
Feb-13-18	Initiated	BTIG Research	Buy	$33
Jan-04-18	Initiated	SunTrust	Buy	$24
Dec-01-17	Resumed	H.C. Wainwright	Buy	$16
Nov-16-16	Reiterated	RBC Capital Mkts	Outperform	$26 → $29
Oct-05-16	Reiterated	Needham	Buy	$22 → $30
Sep-16-16	Initiated	H.C. Wainwright	Buy	$26
Mar-30-15	Initiated	Oppenheimer	Outperform	$28
Mar-30-15	Initiated	Needham	Buy	$22

Show Previous Ratings

Apr-24-24 04:30PM	Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 (Business Wire)
Apr-11-24 04:30PM	Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors (Business Wire)
Apr-10-24 07:00AM	Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum (Business Wire)
Apr-09-24 04:18PM	CORRECTED-Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra named successor (Reuters)
04:05PM	Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer (PR Newswire)
05:41PM	Loading…
Apr-02-24 05:41PM	Insiders Are Buying These 11 Penny Stocks (Insider Monkey)
Mar-29-24 05:43PM	Why Summit Therapeutics Stock Crushed the Market This Week (Motley Fool)
01:35PM	Hedge Fund and Insider Trading News: Cliff Asness, David Tepper, Ray Dalio, Mark Yusko, Baupost Group, Irenic Capital Management, Summit Therapeutics Inc (SMMT), Workday, Inc. (WDAY), and More (Insider Monkey)
Mar-22-24 07:00AM	Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024 (Business Wire) -5.07%
Mar-19-24 09:32AM	Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2023 Earnings Call Transcript (Insider Monkey) -11.79%
Mar-14-24 07:00AM	Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024 (Business Wire) +5.32%
Mar-05-24 07:00AM	Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference (Business Wire) +13.17%
Feb-21-24 08:53AM	Summit Therapeutics Inc. (NASDAQ:SMMT) Q4 2023 Earnings Call Transcript (Insider Monkey) +9.89%
01:56AM	Q4 2023 Summit Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-20-24 08:31AM	Summit Therapeutics Inc (SMMT) Reports Comprehensive 2023 Financial Results and Clinical ... (GuruFocus.com) -26.23%
07:00AM	Loading…
07:00AM	Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023 (Business Wire)
Feb-14-24 10:29AM	Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024 (Business Wire)
07:00AM	Summit Therapeutics to Host Fourth Quarter & Full Year 2023 (Business Wire)
Feb-07-24 07:00AM	Summit Therapeutics to Present at Oppenheimers 34th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-08-24 09:00AM	Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +16.47%
Jan-03-24 07:30AM	Summit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Nov-08-23 12:27PM	Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 09:07AM	Summit Therapeutics Inc (SMMT) Reports Q3 Financial Results and Operational Progress (GuruFocus.com) -12.16%
07:00AM	Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023 (Business Wire)
Nov-02-23 04:41PM	Laura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical Development (Business Wire)
08:00AM	Ivonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023 (PR Newswire)
Oct-31-23 08:00AM	Ivonescimabs Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023 (Business Wire)
Oct-26-23 08:00AM	Summit Therapeutics to Host Q3 2023 Financial Results & Operational Progress Call on November 7, 2023 (Business Wire)
Oct-19-23 08:00AM	H. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical Development (Business Wire)
Oct-16-23 11:01PM	Insider Buying: COO Manmeet Soni Acquires 2,976,190 Shares of Summit Therapeutics Inc (GuruFocus.com)
07:00AM	Loading…
07:00AM	Summit Therapeutics Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating Officer (Business Wire)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Aug-09-23 10:19PM	Q2 2023 Summit Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +10.86%
07:00AM	Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023 (Business Wire)
Aug-02-23 08:00AM	Summit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023 (Business Wire) -6.70%
Jul-11-23 11:48AM	Summit Therapeutics Insiders Up US$558m On US$517m Investment (Simply Wall St.)
Jun-04-23 08:00AM	Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023 (Business Wire)
Jun-01-23 07:30AM	Ivonescimab Updated Data to be Featured at ASCO 2023 (Business Wire)
May-22-23 09:30AM	11 Stocks with Heavy Insider Buying in 2023 (Insider Monkey) -5.36%
May-18-23 09:46AM	After buying recently, Summit Therapeutics Inc. (NASDAQ:SMMT) insiders must be dismayed to see the company's market cap drop to US$1.2b (Simply Wall St.)
May-16-23 01:21PM	Why Shares of Summit Therapeutics Slumped on Tuesday (Motley Fool) -15.85%
11:44AM	Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-11-23 11:18PM	Q1 2023 Summit Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -9.20%
12:20PM	10 Best Stocks to Buy for a Quick Return (Insider Monkey)
07:30AM	Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023 (Business Wire)
May-09-23 07:30AM	Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112) (Business Wire)
May-05-23 05:08PM	Why Shares of Summit Therapeutics Soared This Week (Motley Fool) +23.30%
May-03-23 08:30AM	Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112) (Business Wire) +8.61%
Mar-09-23 03:42PM	10 Penny Stocks with Insider Buying (Insider Monkey) -6.58%
07:30AM	Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022 (Business Wire)
Mar-03-23 08:00AM	Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering (Business Wire) -21.03%
Feb-23-23 08:00AM	Summit Therapeutics Rights Offering Nearing Expiration Date (Business Wire) -5.24%
Feb-01-23 10:25AM	Bullish insiders bet US$97m on Summit Therapeutics Inc. (NASDAQ:SMMT) (Simply Wall St.) +7.04%
Jan-30-23 08:00AM	Summit Therapeutics Announces Timing for Rights Offering for Up to $500 Million (Business Wire)
Jan-20-23 08:00AM	Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody (Business Wire)
Jan-05-23 09:59AM	We Think Summit Therapeutics (NASDAQ:SMMT) Can Afford To Drive Business Growth (Simply Wall St.) -9.61%
07:00AM	Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-30-22 01:25PM	Why Summit Therapeutics Shares Soared This Week (Motley Fool) -19.96%
Dec-09-22 08:27AM	Summit Therapeutics Inc.'s (NASDAQ:SMMT) CEO Robert Duggan is the most upbeat insider, and their holdings increased by 431% last week (Simply Wall St.) +8.59%
Dec-08-22 04:45PM	Why Summit Therapeutics Stock Is Skyrocketing This Week (Motley Fool) +17.21%
Dec-06-22 09:54AM	Summit Therapeutics Shares Surge After Licensing Agreement For Cancer Program (Benzinga) +194.27%
07:30AM	Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody (GlobeNewswire)
Nov-17-22 04:15PM	Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors (GlobeNewswire)
Nov-12-22 07:10AM	Summit Therapeutics Third Quarter 2022 Earnings: US$0.14 loss per share (vs US$0.20 loss in 3Q 2021) (Simply Wall St.)
Nov-09-22 08:30AM	Summit Therapeutics Inc. Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2022 (GlobeNewswire)
Oct-20-22 05:15PM	Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022 (GlobeNewswire)
Oct-18-22 08:16AM	Shareholders in Summit Therapeutics (NASDAQ:SMMT) are in the red if they invested five years ago (Simply Wall St.)
Oct-13-22 08:00AM	Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022 (GlobeNewswire)
Oct-04-22 11:49AM	Summit Therapeutics Seeks Partnership For Phase 3 Infection Candidate Development (Benzinga)
Oct-03-22 04:37PM	Summit Therapeutics Appoints Dr. Robert Booth, Renowned Executive and Scientific Leader, to its Board of Directors (GlobeNewswire)
Sep-12-22 09:17AM	10 Best Penny Stocks to Buy in September (Insider Monkey)
Aug-22-22 01:16PM	Why Summit Therapeutics Stock Popped Today (Motley Fool) +48.18%
Aug-20-22 08:37AM	Trade Alert: The Co-CEO & Executive Chairman Of Summit Therapeutics Inc. (NASDAQ:SMMT), Robert Duggan, Has Just Spent US$92m Buying 140% More Shares (Simply Wall St.)
Aug-19-22 11:58AM	Why Summit Therapeutics Stock Is Soaring Today (Motley Fool) +10.00%
Aug-11-22 08:00AM	Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2022 (GlobeNewswire)
Aug-09-22 01:37PM	Summit Therapeutics Closes Fully-Subscribed $100 Million Rights Offering (GlobeNewswire)
Aug-02-22 09:25AM	Summit Therapeutics Rights Offering Nearing Expiration Date (GlobeNewswire)
Jul-26-22 04:15PM	Summit Therapeutics Appoints Dr. Maky Zanganeh as Co-CEO & President (GlobeNewswire)
Jul-18-22 04:05PM	Summit Therapeutics Announces Commencement of $100 Million Rights Offering (GlobeNewswire)
Jul-14-22 11:35AM	Summit Therapeutics Mulls Additional Trial For Its Once Failed Infection Candidate (Benzinga)
08:30AM	Summit Therapeutics Provides Update on Ridinilazole (GlobeNewswire)
Jun-22-22 04:30PM	Summit Therapeutics Announces $100 Million Rights Offering (GlobeNewswire) +8.00%
Jun-03-22 08:30AM	Summit Therapeutics Upcoming Annual Shareholders Meeting (GlobeNewswire)
Jun-01-22 08:30AM	Summit Therapeutics Appoints Ankur Dhingra as Chief Financial Officer (GlobeNewswire)
May-11-22 04:30PM	Summit Therapeutics Inc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2022 (GlobeNewswire) -8.93%
May-08-22 09:44AM	What Kind Of Shareholders Hold The Majority In Summit Therapeutics Inc.'s (NASDAQ:SMMT) Shares? (Simply Wall St.)
Apr-10-22 08:36AM	Summit Therapeutics Inc. (NASDAQ:SMMT) insiders placed bullish bets worth US$62m in the last 12 months (Simply Wall St.)
Mar-17-22 04:14PM	Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2021 (GlobeNewswire) +7.93%
Feb-24-22 04:51AM	We Think Summit Therapeutics (NASDAQ:SMMT) Needs To Drive Business Growth Carefully (Simply Wall St.) +18.84%
Feb-09-22 08:00AM	Summit Therapeutics Announces Postponement of Its Planned Rights Offering (GlobeNewswire)
Jan-25-22 07:30AM	Summit Therapeutics Announces Rights Offering (GlobeNewswire)
Jan-10-22 08:00AM	Summit Therapeutics Today Presents Its Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference (GlobeNewswire)
Jan-05-22 07:30AM	Summit Therapeutics to Present Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference (GlobeNewswire)
Dec-31-21 02:30PM	ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Summit Therapeutics Inc. with Losses of $100,000 to Contact the Firm (PR Newswire) +5.49%
Dec-28-21 04:04PM	INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Summit Therapeutics Inc. with Losses of $100,000 to Contact the Firm (Business Wire)
Dec-23-21 12:07PM	Investigation Alert: Did You Lose Money on Your Investment? Johnson Fistel, LLP Encourages Investors to Contact the Firm (PR Newswire) +14.77%
Dec-21-21 12:40PM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Summit Therapeutics Inc. (SMMT) Investigation (ACCESSWIRE) -5.41%
Dec-20-21 02:15PM	Summit Therapeutics' Infection Candidate Flunks In Head-To-Head Trial (Benzinga) -47.99%
12:28PM	Why Summit Therapeutics Stock Is Tumbling Today (Motley Fool)
08:30AM	Summit Therapeutics Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection (GlobeNewswire)

Summit Therapeutics, Inc. a biopharmaceutical company, which discovers, develops, and commercializes medicines to treat infectious diseases. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Menlo Park, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zanganeh Mahkam	Chief Executive Officer	Mar 27 '24	Buy	3.72	54,321	201,874	24,923,800	Mar 27 08:28 PM
Zanganeh Mahkam	Chief Executive Officer	Mar 27 '24	Buy	3.72	26,000	96,720	520,814	Mar 27 08:28 PM
Dhingra Ankur	Chief Financial Officer	Mar 26 '24	Buy	3.75	100,000	375,000	354,958	Mar 27 08:27 PM
Zanganeh Mahkam	Chief Executive Officer	Mar 26 '24	Buy	3.75	30,000	112,500	30,000	Mar 27 08:28 PM
Dhingra Ankur	Chief Financial Officer	Dec 13 '23	Buy	2.17	20,400	44,254	254,958	Dec 13 04:49 PM
Zanganeh Mahkam	Chief Executive Officer	Dec 12 '23	Buy	2.07	5,000	10,350	494,814	Dec 13 05:11 PM
Soni Manmeet Singh	Chief Operating Officer	Oct 13 '23	Buy	1.68	2,976,190	4,999,999	2,976,190	Oct 16 04:06 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

PLSE

Pulse Biosciences Inc

SMMT

Summit Therapeutics Inc

Upgrade your FINVIZ experience